Abilify

By Jonah Comstock November 17, 2017
Correction: An earlier version of this article was unclear about differences between Abilify MyCite and the Proteus Digital Medicine Platform.  Earlier this week, Proteus Digital Health and Otsuka Pharmaceuticals announced that Abilify MyCite, a new, sensor-enabled version of Otsuka’s drug for schizophrenia, had received FDA approval for mental health conditions including schizophrenia and...
By Mike Miliard November 14, 2017
The first drug in the US with a digital ingestion tracking system has been approved by the FDA. The pill, Abilify MyCite, is prescribed for treatment of schizophrenia, acute treatment of manic and mixed episodes associated with bipolar I disorder and as an add-on treatment for depression in adults. An ingestible sensor embedded in the pill is able to record that the medication was taken – sending...
By Jonah Comstock October 10, 2017
Otsuka, the Japanese pharma company that makes the antipsychotic drug Abilify, has partnered with Australian digital health company Medibio to use Medibio’s system to assess the efficacy of its flagship product. Medibio uses wearable-derived data about heart rate, motion, and sleep to create objective biomarkers for mental illness. “We have proprietary algorithms and technology that use circadian...
By Jonah Comstock May 23, 2017
One year after the FDA declined to approve Proteus Digital Health and Otsuka's new sensor-embedded formulation of Otsuka's antipsychotic drug Abilify, the companies are giving it another shot, resubmitting the application with additional information. As before, the application is a New Drug Application (NDA) -- both the Proteus system itself and Abilify are already FDA cleared and approved,...
By Jonah Comstock April 27, 2016
The FDA declined to approve what would have been the first mass market drug to incorporate Proteus Digital Health's ingestible sensor. The drug, a collaboration between Proteus and Otsuka Pharmaceuticals, combines the Proteus system with the antipsychotic pharmaceutical Abilify. “While we are disappointed in the FDA’s decision not to approve this digital medicine at this time, both Otsuka and...
By Jonah Comstock September 10, 2015
After years of using its digital health feedback system in clinical trials and studies, Proteus Digital Health, and partner Otsuka Pharmaceuticals, are poised to launch the first mass market drug to incorporate Proteus's ingestible sensor. The companies have submitted a sensor-embedded version of the antidepressant Abilify for FDA approval. “Today, patients suffering from severe mental illnesses...
By Brian Dolan May 1, 2013
Proteus Biomedical's Raisin system Redwood City, California-based Proteus Digital Health announced that it had raised $62.5 million in its latest round of funding led by Oracle with participation from existing investors Otsuka, Novartis, Sino Portfolio and others. MobiHealthNews reported on the first $17.5 million that Proteus raised for this round a year ago, so the $62.5 million includes an...
By Brian Dolan July 6, 2012
Proteus Biomedical's Raisin system Intelligent medicine platform developer Proteus Biomedical has changed its name to Proteus Digital Health, to "better reflect" what the company does, Chief Product Officer David O'Reilly told MobiHealthNews in an email this week. Proteus also inked a deal with Japan-based Otsuka Pharmaceutical, which is known for its Abilify drug for schizophrenia and bipolar...